Migalastat and Renal dysfunction
Result of checking the interaction of drug Migalastat and disease Renal dysfunction for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Migalastat is substantially excreted by the kidneys. No dosage adjustment is required in patients with mild to moderate renal impairment (eGFR at least 30 mL/min/1.73 m2 and above). Migalastat is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis. Systemic exposure was significantly increased in subjects with severe renal impairment (eGFR less than 30 mL/min/1.73 m2). Migalastat has not been studied in patients with Fabry disease who have an eGFR less than 30 mL/min/1.73 m2. Care is recommended when using this agent in patients with renal impairment.